Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 18/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.59 |
| ▸ | EDNRA | P25101 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL848167 | 0.93 | EDNRA (0.60) | MAPK8MAPK9EDNRA | |
| SCHEMBL848642 | 0.90 | MAPK8 (0.59) | MAPK8MAPK9EDNRAMAPK10 | |
| SCHEMBL849817 | 0.90 | MAPK8 (0.75) | MAPK8MAPK9MAPK10 | |
| SCHEMBL849555 | 0.84 | MAPK8 (0.64) | MAPK8MAPK9EDNRAMAPK10 | |
| SCHEMBL14617180 | 0.81 | MAPK8 (0.72) | MAPK8MAPK9 | |
| SCHEMBL846942 | 0.80 | MAPK8 (0.87) | MAPK8MAPK9MAPK10 | |
| SCHEMBL847034 | 0.80 | SMN1; SMN2 (0.52) | EDNRAMAPK10 | |
| SCHEMBL14575606 | 0.79 | MAPK8 (0.72) | MAPK8MAPK9 | |
| SCHEMBL846988 | 0.79 | MAPK8 (0.84) | MAPK8MAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL14576577 | 0.79 | MAPK8 (0.71) | MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2009015917-A2 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009015917-A2 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008138920-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | MAPK8 12/4885MAPK9 1/4885EDNRA 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.